Meyer SL, Wolff D, Ridderbos FJS, et al. - Researchers undertook this single‐center prospective investigation to determine serial serum levels of GDF‐15 (growth differentiation factor 15) among Fontan patients as well as their association with outcome. At baseline (n = 81) and following 2 years (n = 51), serial serum GDF‐15 measurement and clinical evaluation was carried out among participants. Experts assessed the link between GDF‐15 and the combined endpoint of all‐cause death, heart transplant listing, and Fontan‐related hospitalization. Positive correlation of GDF‐15 serum levels was seen with the following: age, age at Fontan initiation, New York Heart Association class, and serum levels of N‐terminal pro‐B‐type natriuretic peptide and γ‐glutamyltransferase. Its negative correlation with exercise capacity was also noted. A median follow‐up of 4.8 years revealed the occurrence of the combined endpoint in 30 patients (37%). The link of elevated serum levels of GDF‐15 with worse functional status as well as its ability to predict Fontan‐related events was evident among Fontan patients. As indicated by serial measurements, there was a link between a rise in GDF‐15 serum level and increased risk for adverse outcome.